Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Synthesis, crystal structure and DFT studies of a methylphenyl piperazinyl dithiocarbamato zinc(ii) precursor for zinc sulfide nanophotocatalysts used for the degradation of trypan blue and rhodamine 6G dyes.

RSC advances·2026
Same author

Biochar-capped iron oxide nanocomposites prepared by ultrasonic method as nanophotocatalysts for the degradation of organic dyes using response surface methodology.

RSC advances·2026
Same author

Synthesis, crystal structure and DFT studies of a methylphenyl piperazinyl dithiocarbamato zinc(ii) precursor for zinc sulfide nanophotocatalysts used for the degradation of trypan blue and rhodamine 6G dyes.

RSC advances·2026
Same author

Synthesis, characterization and computational studies of copper(ii) terpyridine-based metal-organic frameworks for the removal of emerging herbicide contaminant from aqueous solution.

RSC advances·2025
Same author

Ultrasensitive electrochemical detection of bisphenol A using copper(ii) metal-organic framework ternary quantum dot (Cu-MOF/TQD) composite-modified gold electrodes.

RSC advances·2025
Same author

Photocatalytic degradation of single and binary mixture of malachite green and rhodamine B dyes by biochar-capped iron oxide nanocomposites.

Environmental science and pollution research international·2025

Related Experiment Video

Updated: May 17, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Inhibitory activities and possible anticancer targets of Ru(II)-based complexes using computational docking method.

Adebayo A Adeniyi1, Peter A Ajibade

  • 1Department of Chemistry, University of Fort Hare, Private Bag X1314, Alice 5700, South Africa.

Journal of Molecular Graphics & Modelling
|October 20, 2012
PubMed
Summary

Researchers explored Ruthenium(II) complexes as novel anticancer agents, identifying potential protein targets beyond DNA using computational docking. Some complexes show promise for both anticancer and antibacterial applications.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Related Experiment Videos

Last Updated: May 17, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Biochemistry

Background:

  • Cisplatin and its derivatives are non-selective cytotoxic anticancer agents.
  • Ruthenium(II) complexes are investigated as alternatives with different biological targets.
  • Understanding the specific anticancer targets of Ru(II) complexes remains a research challenge.

Purpose of the Study:

  • To identify alternative protein targets for Ru(II)-based anticancer complexes beyond DNA.
  • To address the lack of understanding regarding the anticancer mechanisms of Ru(II) complexes.
  • To evaluate potential pharmacokinetic advantages and dual anticancer/antibacterial activities.

Main Methods:

  • Computational docking studies were employed to predict interactions between Ru(II) complexes and various protein targets.
  • Analysis of binding affinities and interactions with potential targets including enzymes and DNA-Gyrase.
  • Evaluation of interactions with human serum albumin (rHA) for pharmacokinetic insights.

Main Results:

  • Docking studies identified Cathepsin B (CatB), HP-NCP, and kinase as validated potential targets.
  • Novel potential targets, including Ribonucleotide Reductase (RNR) and Histone Deacetylase 7 (HDAC7), were proposed.
  • Most complexes exhibited favorable interactions with human serum albumin (rHA), suggesting improved pharmacokinetic properties.
  • Several complexes showed favorable binding with DNA-Gyrase, indicating potential dual antibacterial activity.

Conclusions:

  • Ru(II) complexes offer promising alternative anticancer strategies by targeting proteins other than DNA.
  • Computational docking is a valuable tool for elucidating anticancer mechanisms and identifying novel targets.
  • The identified Ru(II) complexes demonstrate potential for enhanced pharmacokinetics and dual anticancer/antibacterial efficacy.